The Drake health registry study: Cause-specific mortality experience of workers potentially exposed to beta-naphthylamine

American Journal of Industrial Medicine

Volumn 44, Issue 3, 2003, Pages 282-290

  Cassidy, Laura D ^a   Youk, Ada O ^a   Marsh, Gary M ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Beta naphthylamine; Bladder cancer; Cancer screening; Mortality; Occupational epidemiology

Indexed keywords

2 NAPHTHYLAMINE;

ADULT; ARTICLE; BEHAVIOR; BLADDER CANCER; CANCER SCREENING; CAUSE OF DEATH; CHEMICAL INDUSTRY; FEMALE; HUMAN; INDUSTRIAL HYGIENE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; OCCUPATIONAL CANCER; OCCUPATIONAL EXPOSURE; REGISTER; RESPIRATORY TRACT CANCER; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

2-NAPHTHYLAMINE; ADULT; CARCINOGENS; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HUMANS; MALE; OCCUPATIONAL EXPOSURE; PENNSYLVANIA; REGISTRIES; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0042697440     PISSN: 02713586     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajim.10268     Document Type: Article

References (36)

1. Bi W, Hayes RB, Feng P, Qi Y, You X, Zhen J, Zhang M, Qu B, Fu Z, Chen M. 1992. Mortality and incidence of baldder cancer in benzidine-exposed workers in China. Am J Ind Med 21:481-489.
2. Budnick LD, Sokol DC, Falk H, Logue JN, Fox JM. 1984. Cancer and birth defects near the Drake Superfund Site, Pennsylvania. Arch Environ Health 39:409-413.
3. Bulbulyan MA, Figgs LW, Zahm SH, Savitskaya T, Goldfarb A, Astashevsky S, Zaridze D. 1995. Cancer incidence and mortality among beta-naphythylamine and benzidine dye workers in Moscow. Int J Epidemiol 24:266-275.
4. Case RAM, Hosker ME, McDonald DB, Pearson JT. 1954. Tumours of the urinary bladder in workmen engaged in the manufacture and use for certain dyestuff intermediates in the British chemical industry: The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylaime. Br J Ind Med 11:75-104.
5. Hemstreet GP III, West SS, Weems WL, Echols CK, McFarland S, Lewin J, Lindseth G. 1983. Quantitative fluorescence measurements of AO-stained normal and malignant bladder cells. Int J Cancer 31:577-585.
6. Hemstreet GP III, West SS, Cook MS. 1986. Improved nuclear fluorescence screening technique. J Occup Med 28:1004-1010.
7. Hemstreet GP III, Hurst RE, Bass RA, Rao JY. 1990. Quantitative fluorescence image analysis in bladder cancer screening. J Occup Med 32:822-828.
8. Hemstreet GP III, Rao JY, Hurst RE, Bonner RB, Jones PL, Vaidya AM, Fradet Y, Moon RC, Kelloff GJ. 1992. Intermediate endpoint biomarkers for chemoprevention. J Cell Biochem Suppl 16:93-110.
9. Hemstreet GP, Bonner RB, Hurst RE, O'Dowd GA. 1996. Cytology of bladder cancer. In: Vogelzang NJ, Scardino PG, Shipley WU, Coffey DS, editors. Comprehensive textbook of genitourinary oncology. Baltimore, MD: Williams & Wilkins. p 338-350.
10. International Agency for Research on Cancer. 1987. Overall evaluations of carcinogenicity: An updating of IARC monographs, volumes 1-42. Lyon, France: IAEC: IARC Mongr Eval Risks Humans. Supplement 7.
11. Leviton LC, Marsh GM, Talbott E, Pavlock D, Callahan C. 1991. The Drake Chemical Workers Health Registry Study: II. Coping with community tension in health protection. Am J Public Health 81:68-692.
12. Leviton LC, Chen HT, Marsh GM, Talbott EO. 1993. Evaluation issues in the Drake Chemical Workers Nofification and Health Registry Study. Am J Ind Med 23:197-204.
13. Lieben J. 1963. An epidemiologic study of occupational bladder cancer. Acta Union Int Cancer 19:759-760.
14. Logue JN, Fox JM. 1986. Residential health study of families living near the Drake Chemical Superfund Site in Lock Haven, PA. Arch Environ Health 41:222-228.
15. Mancuso TF, El-Attar AA. 1967. Cohort study of workers exposed to beta-naphthylamine and benzidine. J Occup Med 9:277-285.
16. Marsh GM, Cassidy LD. 2003. The Drake Health Registry Study: Findings from fifteen years of continuous bladder cancer screening. Am J Ind Med 43(2):142-148.
17. Marsh GM, Constantino JP, Lyons EE, Logue JN, Fox JM. 1988. Health effects of exposure to the Drake Chemical Company superfund site: Morbidity among former employees and family members. J Environ Health 50:389-394.
18. Marsh GM, Leviton LC, Talbott EO, Callahan C, Pavlock D, Hemstreet G, Logue JN, Fox J, Schulte P. 1991. Drake chemical workers' health registry study: I. notification and medical surveillance of a group of workers at high risk of developing bladder cancer. Am J Ind Med 19:291-301.
19. Marsh GM, Youk AO, Stone RA, Sefcik S, Alcom C. 1998. OCMAP-PLUS, a new program for the comprehensive analysis of occupational cohort data. J Occup Environ Med 40:351-362.
20. Marsh GM, Ehland J, Sefcik S. 2001. Mortality and Population Data System. Technical Report 2001. Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA.
21. Matanoski GM, Elliott EA. 1981. Bladder cancer epidemiology. Epidemiol Rev 3:203-229.
22. Meigs JQ, Marrett LD, Ulrich FU, Flannery JT. 1986. Bladder tumor incidence among workers exposed to benzidine: A thirty-year follow-up. JNCI 76:1-8.
23. Morinaga K, Oshima A, Hara I. 1982. Multiple primary cancers following exposure to benzidine and beta-naphythylamine. Am J Ind Med 3(3):243-246.
24. Naito S, Tanak K, Koga H, Kotoh S, Hirohata T, Kumazawa J. 1994. Cancer occurrence among dyestuff workers exposed to aromatic amines. A long term follow-up study. Cancer 76(8):1445-1452.
25. Rubino GF, Scansetti G, Piolatto G, Pira E. 1982. The carcinogenic affect of aromatic amines: An epidemiologic study on the role of o-toluidine and 4,4′-methylene bis(2-methylaniline) in inducing bladder cancer in man. Environ Res 27:241-254.
26. Schall LC, Marsh GM, Henderson VL. 1997. A two-stage protocol for verifying vital status in large historical cohort studies. JOEM 39:1097-1102.
27. Schall LC, Buchanich JM, Marsh GM, Bittner GM. 2001. Utilizing Multiple Vital Status Tracing Services is Necessary for Attaining Optimal Mortality Follow-up in Cohort Studies. Ann Epidem 11(5):292-296.
28. Schulte PA, Ringen K, Hemstreet GP, Altekruse EB, Gullen WH, Tillett S, Allsbrook WC, Jr., Crosby JH, Witherington R, Stringer W. 1986. Risk factors for bladder cancer in a cohort exposed to aromatic amines. Cancer 58:2156-2162.
29. Stern FB, Murthy LI, Beaumont JJ, Schulte PA, Halperin WE. 1985. Notification and risk assessment for bladder cancer of a cohort exposed to aromatic amines. J Occup Med 27:495-500.
30. Tsachiya K, Okubo T, Ishizu S. 1975. An epidemiologic study of occupational bladder tumours in the dye industry of Japan. Br J Ind Med 32:203-209.
31. USDHHS. 1981. Centers for Disease Control/National Institute for Occupational Safety and Health Interim Report HETA 81-248, Cincinnati, OH.
32. U.S. Environmental Protection Agency. 1985. Remedial investigation report (Site: Drake Chemical Company, Lock Haven, PA), Office of Solid Waste and Emergency Response, Washington, DC, Phase 1-1984, Phase II-1985.
33. Vineis P. 1992. Epidemiological models of carcinogenesis: The example of bladder cancer. Cancer Epidemiol Biomarkers Prev 1: 149-153.
34. Vineis P, Pirastu R. 1997. Aromatic amines and cancer. Cancer Causes Control 8(3):346-355.
35. Vineis P, Esteve J, Hartge P, Hoover R, Siverman DT, Terracini B. 1988. Effects of timing and type of tobacco in cigarette-induced bladder cancer. Cancer Res 48:3849-3852.
36. Xue-Yun Y, Ji-Gang C, Yong-Ning Hu. 1990. Studies on the relation between bladder cancer and benzidine or its derived dyes in Shanghai. Br J Ind Med 47:544-552.